Seminars in Nuclear Medicine
Volume 39, Issue 3 , Pages 195-203 , May 2009

Interventional Nuclear Brain Imaging

  • David K. Leung, MD, PhD
    • ,
  • Ronald L. Van Heertum, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ronald L. Van Heertum, MD, Department of Radiology, Columbia University Medical Center, Harkness Pavilion 3-319, 180 Fort Washington Avenue, New York, NY 10032

References 

  1. Matte GG, Barnes DC, Abrams DN. Pharmacologic interventions in nuclear medicine assessment of cardiac perfusion. J Pharmacy Pharma Sci. 2001;4:255–262
  2. Yudd AP, Van Heertum RL, Masdeu JC. Interventions and functional brain imaging. Semin Nucl Med. 1991;21:153–158
  3. Tawes RL, Lull R. Value of single photon emission computerized imaging in the treatment of patients undergoing carotid endarterectomy. J Vasc Surg. 1996;24:219–225
  4. Marti-Fabregas J, Catafau AM, Mari C, et al. Cerebral perfusion and haemodynamics measured by SPET in symptom-free patients with transient ischaemic attack: Clinical implications. Eur J Nucl Med. 2001;28:1828–1835
  5. Mountz JM. Nuclear medicine in the rehabilitative treatment evaluation in stroke recovery (Role of diaschisis resolution and cerebral reorganization). Eura Medicophys. 2007;43:221–239
  6. Fülesdi B, Limburg M, Bereczki D, et al. Cerebrovascular reactivity and reserve capacity in type II diabetes mellitus. J Diabetes Complications. 1999;13:191–199
  7. Vorstrup S, Brun B, Lassen NA. Evaluation of the cerebral vasodilatory capacity by the acetazolamide test before EC-IC bypass surgery in patients with occlusion of the internal carotid artery. Stroke. 1986;17:1291–1298
  8. O JH, Jang KS, Yoo I-R, et al. Assessment of cerebrovascular reserve before and after STA-MCA bypass surgery by SPECT and SPM analysis. Korean J Radiol. 2007;8:458–465
  9. Devous MD. Single-photon emission computed tomography in neurotherapeutics. J Am Soc Exp NeuroTher. 2005;2:237–249
  10. Knapp WH, von Kummer R, Kubler W. Imaging of cerebral blood flow-to-volume distribution using SPECT. J Nucl Med. 1986;27:465–470
  11. Oki N, Matsumoto M, Hashikawa K, et al. Carbon dioxide reactivity by consecutive Technetium-99m-HMPAO SPECT in patients with a chronically obstructed major cerebral artery. J Nucl Med. 1994;35:32–40
  12. Fallon BA, Lipkin RB, Corbera KM, et al: Regional cerebral blood flow and metabolic rate in persistent Lyme encephalopathy. Arch Gen Psychiatry (in press)
  13. Fallon BA, Keilp J, Prohovnik I, et al. Regional cerebral blood flow and cognitive deficits in chronic Lyme disease. J Neuropsychiatry Clin Neurosci. 2003;15:326–332
  14. Burt RW, Witt RM, Cikrit DF, et al. Carotid artery disease: evaluation with acetazolamide-enhanced Tc-99m HMPAO SPECT. Radiology. 1992;182:461–466
  15. Hauge A, Nicolaysen G, Thoresen M. Acute effects of acetazolamide on cerebral blood flow in man. Acta Physiol Scand. 1983;117:233–239
  16. Hayashida K, Tanaka Y, Hirose Y, et al. Vasoreactive effect of acetazolamide as a function of time with sequential PET 15O-water measurement. Nucl Med Commun. 1996;17:1047–1051
  17. Soricelli A, Postiglione A, Cuocolo A, et al. Effect of adenosine on cerebral blood flow as evaluated by single-photon emission computed tomography in normal subjects and in patients with occlusive carotid disease: a comparison with acetazolamide. Stroke. 1995;26:1572–1576
  18. Kimura T, Shinoda J, Funakoshi T. Prediction of cerebral infarction due to vasospasm following aneurysmal subarachnoid haemorrhage using acetazolamide-activated 123-I-IMP SPECT. Acta Neurochir. 1993;123:125–128
  19. Mayer SA, Van Heertum RL, Tikofsky RS, et al. Presymptomatic detection of ischemia from vasospasm after subarachnoid hemorrhage with acetazolamide-activated SPECT. (abstr) Stroke. 1997;28:253
  20. Reinprecht A, Czech T, Asenbaum S, et al. Low cerebrovascular reserve capacity in long-term follow-up after subarachnoid hemorrhage. Surg Neurol. 2005;64:116–120
  21. Lewis DH, Paul Elliott J, Newell DW, et al. Interventional endovascular therapy: SPECT cerebral blood flow imaging compared with transcranial Doppler monitoring of balloon angioplasty and intraarterial papaverine for cerebral vasospasm. J Stroke Cerebrovasc Dis. 1999;8:71–75
  22. Hacein-Bey L, Nour R, Pile-Spellman J, et al. Adaptive changes of autoregulation in chronic cerebral hypotension with arteriovenous malformations: An acetazolamide-enhanced single-photon emission CT study. AJNR Am J Neuroradiol. 1995;16:1865–1874
  23. Cuocolo A, Soricelli A, Pace L, et al. Adenosine technetium-99m-methoxy isobutyl isonitrile myocardial tomography in patients with coronary artery disease: comparison with exercise. J Nucl Med. 1994;35:1110–1115
  24. Duncan JS. Modern treatment strategies for patients with epilepsy: a review. J R Soc Med. 1991;84:159–162
  25. Wyllie E. Surgical treatment of epilepsy in pediatric patients. Can J Neurol Sci. 2000;27:106–110
  26. Henry TR, Van Heertum RL. Positron emission tomography and single photon emission computed tomography in epilepsy care. Semin Nucl Med. 2003;33:88–104
  27. McNally KA, Paige AL, Varghese G, et al. Localizing value of ictal-interictal SPECT analyzed by SPM (ISAS). Epilepsia. 2005;46:1450–1464
  28. Kurian M, Spinelli L, Delavelle J, et al. Multimodality imaging for focus localization in pediatric pharmacoresistant epilepsy. Epileptic Disord. 2007;9:20–31
  29. Sood S, Chugani HT. Functional neuroimaging in the preoperative evaluation of children with drug-resistant epilepsy. Child Nervous Syst. 2006;22:810–820
  30. Nandhagopal R, McKeown MJ, Stoessl AJ. Functional imaging in Parkinson disease. Neurology. 2008;70:1478–1488
  31. Rinne JO, Ruottinen H, Bergman J, et al. Usefulness of a dopamine transporter PET ligand [18F]beta-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67:737–741
  32. Filippi L, Manni C, Pierantozzi M, et al. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nucl Med Commun. 2005;26:421–426
  33. Ma Y, Tang C, Spetsieris PG, et al. Abnormal metabolic network activity in Parkinson's disease: Test–retest reproducibility. J Cereb Blood Flow Metab. 2007;27:597–605
  34. Eckert T, Eidelberg D. Neuroimaging and therapeutics in movement disorders. NeuroRx. 2005;2:361–371
  35. DeLong . Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13:281–285
  36. Feigin A, Fukuda M, Dhawan V, et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology. 2001;57:2083–2088
  37. Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [18F]FDG-PET. Mov Disord. 2001;16:1014–1022
  38. Cools R, Clark L, Owen AM, et al. Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci. 2002;22:4563–4567
  39. Rahman S, Sahakian BJ, Hodges JR, et al. Specific cognitive deficits in mild frontal variant frontotemporal dementia. Brain. 1999;122:1469–1493
  40. Freed CR, Leehey MA, Zawada M, et al. Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation?. J Neurol. 2003;250(suppl 3):III44–III46
  41. Riggs HE, Rupp C. Variation in form of circle of Willis (The relation of the variations to collateral circulation: Anatomic analysis). Arch Neurol. 1963;8:8–14
  42. Hendrikse J, van Raamt AF, van der Graaf Y, Mali W, van der Grond J. Distribution of cerebral blood flow in the Circle of Willis. Radiology. 2005;235:184–189
  43. Kayembe KNT, Sasahara M, Hazama F. Cerebral aneurysms and variations in the Circle of Willis. Stroke. 1984;15:846–850
  44. Jain R, Hoeffner EG, Deveikis JP, et al. Carotid perfusion CT with balloon occlusion and acetazolamide challenge test: Feasibility. Radiology. 2004;231:906–913
  45. Askienazy S, Lebtahi R, Meder J-F. SPECT HMPAO and balloon test occlusion: Interest in predicting tolerance prior to permanent cerebral artery occlusion. J Nucl Med. 1993;34:1243–1245
  46. Sugawara Y, Kikuchi T, Ueda T, et al. Usefulness of brain SPECT to evaluate brain tolerance and hemodynamic changes during temporary balloon occlusion test and after permanent carotid occlusion. J Nucl Med. 2002;43:1616–1623
  47. Lorberboym M, Pandit N, Machac J, et al. Brain perfusion imaging during preoperative temporary balloon occlusion of the internal carotid artery. J Nucl Med. 1996;37:415–419
  48. Swearingen B, Heros RC. Common carotid occlusion for unclippable carotid aneurysms: An old but still effective operation. Neurosurgery. 1987;21:288–295
  49. Yasuda H, Kuroda S, Ushikoshi S, et al. Combined surgical and endovascular treatment of infected pseudoaneurysm after carotid endarterectomy. Neurol Med Chir. 2005;45:37–40
  50. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002;165:1217–1239
  51. Macey PM, Henderson LA, Macey KE, et al. Brain morphology associated with obstructive sleep apnea. Am J Respir Crit Care Med. 2002;166:1382–1387
  52. O'Donoghue FJ, Briellmann RS, Rochford PD, et al. Cerebral structural changes in severe obstructive sleep apnea. Am J Respir Crit Care Med. 2005;171:1185–1190
  53. Dang-Vu TT, Desseilles M, Petit D, et al. Neuroimaging in sleep medicine. Sleep Med. 2007;8:349–372
  54. Joo EY, Tae WS, Han SJ, et al. Reduced cerebral blood flow during wakefulness in obstructive sleep apnea-hypopnea syndrome. Sleep. 2007;30:1515–1520
  55. Ficker JH, Feistel H, Möller C, et al. Changes in regional CNS perfusion in obstructive sleep apnea syndrome: Initial SPECT studies with injected nocturnal 99mTc-HMPAO. Pneumologie. 1997;51:926–930
  56. Fukuda M, Mentis MJ, Ma Y, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A PET study of resting-state glucose metabolism. Brain. 2001;124:1601–1609
  57. Hilker R, Voges J, Weisenbach S, et al. Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: Evidence from a FDG-PET study in advanced Parkinson's disease. J Cereb Blood Flow Metab. 2004;24:7–16
  58. Trost M, Su S, Su P, et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. NeuroImage. 2006;31:301–307
  59. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: Implications for neurocircuitry models of depression. Brain Structure and Function. 2008;213:93–118
  60. Elizagarate E, Cortes J, Gonzalez Pinto A, et al. Study of the influence of electroconvulsive therapy on the regional cerebral blood flow by HMPAO-SPECT. J Affect Disord. 2001;65:55–59
  61. Nobler MS, Oquendo MA, Kegeles LS, et al. Decreased regional brain metabolism after ECT. Am J Psychiatry. 2001;158:305–308
  62. Krystal AD, Weiner RD. EEG correlates of the response to ECT: A possible antidepressant role of brain-derived neurotrophic factor. J ECT. 1999;15:27–38
  63. Sackeim HA, Luber B, Katzman GP, et al. The effects of electroconvulsive therapy on quantitative electroencephalograms: Relationship to clinical outcome. Arch Gen Psychiatry. 1996;53:814–824
  64. Nobler MS, Sackeim HA, Prohovnik I, et al. Regional cerebral blood flow in mood disorders, III (Treatment and clinical response). Arch Gen Psychiatry. 1994;51:884–897
  65. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(3 suppl 2):S69–S74
  66. Stern Y, Moeller JR, Anderson KE, et al. Different brain networks mediate task performance in normal aging and AD: Defining compensation. Neurology. 2000;55:1291–1297
  67. Kemppainen NM, Aalto S, Karrasch M, et al. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol. 2008;63:112–118
  68. Galynker II, Cai J, Ongseng F, et al. Hypofrontality and negative symptoms in major depressive disorder. J Nucl Med. 1998;39:608–612
  69. Yao W, Pan H, Yang Y, et al. Reduced frontal perfusion in depressed postmenopausal women: A SPECT study with WCST. Maturitas. 2008;59:83–90
  70. Bench CJ, Frackowiak RS, Dolan RJ. Changes in regional cerebral blood flow on recovery from depression. Psychol Med. 1995;25:247–261
  71. Liu Z, Carl Tam W, Xie Y, Zhao J. The relationship between regional cerebral blood flow and the Wisconsin Card Sorting Test in negative schizophrenia. Psychiatry Clin Neurosci. 2002;56:3–7
  72. Toone BK, Okocha CI, Sivakumar K, et al. Changes in regional cerebral blood flow due to cognitive activation among patients with schizophrenia. Br J Psychiatry. 2000;177:222–228
  73. Angrist B, van Kammen DP. CNS stimulants as tools in the study of schizophrenia. Trends Neurosci. 1984;7:388–390
  74. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. J Neuropsychiatry Clin Neurosci. 1996;8:223–226
  75. Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry. 1998;155:761–767
  76. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci. 1997;94:2569–2574
  77. Breier A, Adler CM, Weisenfeld N, et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach. Synapse. 1998;29:142–147
  78. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biol Psychiatry. 2000;48:627–640
  79. van Berckel BN, Kegeles LS, Waterhouse R, et al. Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology. 2006;31:967–977
  80. Parsey RV, Kegeles LS, Hwang DR, et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J Nucl Med. 2000;41:1465–1477
  81. Suhara T, Takano A, Sudo Y, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003;60:386–391
  82. Tauscher J, Pirker W, de Zwaan M, et al. In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuropsychopharmacol. 1999;9:177–179
  83. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [11C]DASB PET imaging study. Am J Psychiatry. 2001;158:1843–1849
  84. Stein DJ, Van Heerden B, Wessels CJ, et al. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: Investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:1079–1099
  85. Stein DJ, van Heerden B, Hugo C, et al. Functional brain imaging and pharmacotherapy in trichotillomania (Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram). Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:885–890
  86. Carey PD, Warwick J, Niehaus DJ, et al. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry. 2004;4:30
  87. Vythilingum B, Warwick J, van Kradenburg J, et al. SPECT scans in identical twins with trichotillomania. J Neuropsychiatry Clin Neurosci. 2002;14:340–342
  88. Van der Linden G, van Heerden B, Warwick J, et al. Functional brain imaging and pharmacotherapy in social phobia: Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:419–438
  89. Zubieta JK, Ketter TA, Bueller JA, et al. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry. 2003;60:1145–1153
  90. London ED, Simon SL, Berman SM, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004;61:73–84

PII: S0001-2998(08)00154-2

doi: 10.1053/j.semnuclmed.2008.12.004

Seminars in Nuclear Medicine
Volume 39, Issue 3 , Pages 195-203 , May 2009

Article Tools

* Image Usage & Resolution